Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc announces FDA approval for VIMIZIM


Friday, 14 Feb 2014 04:30pm EST 

Biomarin Pharmaceutical Inc:Says the U.S. Food and Drug Administration has approved VIMIZIM for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).